Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>OSE Immunotherapeutics now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a key catalyst and due in Q120. Another three trials were initiated over the last 12 months, which brought OSE a total of €27m in payments from partners (plus another €5.4m from Bpifrance). These trials include a Phase I study with OSE-127 (partnered with Servier), a Phase I study with BI 765063 (previously OSE-172; with Boehringer Ingelheim, BI) and a Phase II study with Tedopi in pancreatic cancer (GERCOR). We raise our valuation of OSE to €198m or €13.2/share (previously €190m).</p>

OSE Immunotherapeutics now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a key catalyst and due in Q120. Another three trials were initiated over the last 12 months, which brought OSE a total of €27m in payments from partners (plus another €5.4m from Bpifrance). These trials include a Phase I study with OSE-127 (partnered with Servier), a Phase I study with BI 765063 (previously OSE-172; with Boehringer Ingelheim, BI) and a Phase II study with Tedopi in pancreatic cancer (GERCOR). We raise our valuation of OSE to €198m or €13.2/share (previously €190m).

OSE Immunotherapeutics  - R&D progress triggers milestone payment windfall

France

OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

OSE Immuno (OSE FP)

OSE Immunotherapeutics - R&D progress triggers milestone payment windfall

OSE Immunotherapeutics now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)